<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Ascentage Pharma Group International (AAPG)</title>
    <description>Latest news, press releases, and SEC filings for Ascentage Pharma Group International (AAPG)</description>
    <link>https://caymanjournal.com/stock/AAPG</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Mon, 27 Apr 2026 22:45:05 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/AAPG/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>6-K — ASCENTAGE PHARMA GROUP INTERNATIONAL</title>
      <description># 📰 What This Document Is
This document is a filing (6-K) and a voluntary announcement detailing scientific research presented by Ascentage Pharma Group International (AAPG). Essentially, the company is sharing its latest, most promising preclinical findings from a poster presentation at the Americ</description>
      <link>https://caymanjournal.com/stock/AAPG/sec-filing/0001213900-26-045375</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/AAPG/sec-filing/0001213900-26-045375</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>